EMRELIS

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerAdvanced Solid TumorsSmall Cell Lung Cancer

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Trodelvy

Gilead

Phase 3

102

EMRELIS

AbbVie

Phase 3

53

Uliledlimab

TTJ Biopharma Co., Ltd.

Phase 3

24

HD204

PPrestige Biopharma Limited

Phase 3

15

Remeron

OOrganon and Co

Preclinical

16

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—8

Treatment

GSK

Preclinical

19

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

2Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer5 trials

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn·AbbVie·Phase 3·NCT06093503

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Active, not recruiting·AbbVie·Phase 2·NCT03539536·270 enrolled

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Terminated·AbbVie·Phase 2·NCT05513703·9 enrolled

Show 2 more trials

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting·AbbVie·Phase 3·NCT04928846·768 enrolled

A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting·AbbVie·Phase 2·NCT06568939·150 enrolled

ESS1 trial

Expanded Access to Telisotuzumab Vedotin

Available·AbbVie··NCT04830202

Small Cell Lung Cancer1 trial

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Not yet recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07323641·60 enrolled

Advanced Solid Tumors1 trial

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Active, not recruiting·AbbVie·Phase 1·NCT02099058·237 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News